Propanc Biopharma, Inc.

Contributing Author

Recent Articles by Propanc Biopharma, Inc.

Jul-21	Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal PPCB GlobeNewswire
Jul-07	Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd PPCB GlobeNewswire
Jul-02	Propanc Biopharma Initiates $5.0 Million Share Repurchase Program PPCB +22.92% GlobeNewswire
Jun-16	Propanc Biopharma's CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study PPCB -10.23% GlobeNewswire
Jun-11	Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program PPCB +80.00% GlobeNewswire
Jun-02	Propanc Biopharma's CEO Attends Keynote Address, "Rejuvenation and Health: Science for an Ageing Society," at the University of Granada, Spain PPCB GlobeNewswire
May-20	Propanc Biopharma's CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade PPCB -12.22% GlobeNewswire
May-19	Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 - 40 Advanced Cancer Patients PPCB GlobeNewswire
May-15	Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results PPCB -6.98% GlobeNewswire
May-13	Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans PPCB -21.40% GlobeNewswire
Mar-24	Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaen and Granada, Spain PPCB -5.94% GlobeNewswire
Mar-12	Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy PPCB -13.57% GlobeNewswire
Mar-10	Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study PPCB -20.47% GlobeNewswire
Mar-03	Propanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models PPCB -5.16% GlobeNewswire
Feb-18	Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results PPCB GlobeNewswire
Feb-05	Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market PPCB +5.71% GlobeNewswire
Jan-27	Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months - Strengthening Global Protection for Breakthrough Proenzyme Formulations PPCB +6.52% GlobeNewswire
Jan-20	Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia PPCB GlobeNewswire
Jan-15	Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer PPCB -17.13% GlobeNewswire
Jan-13	Propanc Biopharma Provides Shareholder Update PPCB GlobeNewswire
Dec-22	Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal PPCB -8.45% GlobeNewswire
Dec-04	Propanc Biopharma Investigates "Mesenchymal Drift" to Reverse Chronic Diseases Defined by Altos Labs PPCB GlobeNewswire
Dec-01	Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis PPCB +5.47% GlobeNewswire
Nov-17	Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results PPCB GlobeNewswire
Nov-10	Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company's R&D Pipeline PPCB -12.43% GlobeNewswire
Nov-04	Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV) PPCB -6.19% GlobeNewswire
Oct-15	CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital PPCB PPCB -8.67% GlobeNewswire
Oct-15	Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital PPCB GlobeNewswire
Oct-07	Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy PPCB GlobeNewswire
Sep-17	Propanc Biopharma Receives Certificate of Grant for "Proenzyme Composition" Patent from US Patent & Trademark Office PPCB GlobeNewswire
Sep-02	Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum PPCB -9.60% GlobeNewswire
Aug-25	Propanc Biopharma Provides Shareholder Update PPCB GlobeNewswire
Aug-19	Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ PPCB -37.26% GlobeNewswire

Propanc Biopharma, Inc.

Recent Articles by Propanc Biopharma, Inc.

Upgrade your Finviz experience